Healthia (ASX:HLA) - Managing Director & Group CEO, Wesley Coote
Managing Director & Group CEO, Wesley Coote
Source: Healthia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia (HLA) raises $44.5 million through a placement and the institutional component of its fully underwritten entitlement offer
  • The company recently flagged a $60 million capital raise to partially fund the acquisition of the Back in Motion Health Group and its 64 physiotherapy clinics
  • This purchase is set to position HLA as a leading provider of physiotherapy services in Australia and expand its presence to WA and New Zealand
  • Healthia will raise the remaining $15.5 million through the retail component of its entitlement offer which will be open from September 27 until October 6
  • Company shares are down 1.88 per cent to trade at $2.09

Healthia (HLA) has completed a placement and the institutional component of its fully underwritten one-for-4.3 pro rata non-renounceable entitlement offer.

As announced at the start of the week, Healthia is launching a $60 million capital raise to fund the acquisition of the Back in Motion Health Group and its 64 physiotherapy clinics throughout Australia and New Zealand for a cash and share consideration of $88.4 million.

Healthia considers the buy to be a strategic way of positioning it as a leading provider of physiotherapy services in Australia and expanding its presence to the WA and New Zealand markets.

The placement and institutional entitlement offer raised a combined total of about $44.5 million at a price of $1.80 per share.

The offer price represents an 18.2 per cent discount to the last closing price of $2.20 on September 17 and a 9.3 per cent discount to the five-day volume-weighted average price of $1.98.

Broken down, Healthia agreed to issue roughly 12.4 million shares to raise $22.3 million without the need for shareholder approval. The institutional offer raised $22.2 million through the issue of about 12.34 million shares and saw a significant take-up of entitlements by institutional shareholders.

The company expects to raise the remaining $15.5 million through the retail component of its entitlement offer which will be open from September 27 until October 6.

Company shares were down 1.88 per cent to trade at $2.09 at 1:50 pm AEST.

HLA by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…